Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C317/00—Sulfones; Sulfoxides
  • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
  • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C317/00—Sulfones; Sulfoxides
  • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/10—Drugs for disorders of the urinary system of the bladder
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C317/00—Sulfones; Sulfoxides
  • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
  • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
  • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2601/00—Systems containing only non-condensed rings
  • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
  • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Definitions

• the present invention relates to novel ⁇ -hydroxy, amino, and halo derivatives of ⁇ -sulfonyl hydroxamic acids, to pharmaceutical compositions containing them and to the method of using them.
• the compounds of the invention are inhibitors of matrix metalloproteinases involved in tissue degradation.
• Hydroxamic acid derivatives are a class of known therapeutically active MMPs inhibitors and there are numerous references in the art disclosing a variety of hydroxamic acid derivatives.
• European Patent Publication No. 0,606,046 A1 discloses arylsulfonamido-substituted hydroxamic acids useful as matrix metalloproteinase inhibitors.
• International Publication Nos. WO 95/35275 and WO 95/35276 disclose sulfonamide hydroxamic acid and carboxylic acid derivatives useful as matrix metalloproteinases inhibitors. All these references relate to sulfonamide hydroxamic acids.
• the compounds of this invention are novel and distinct from all other sulfonamide hydroxamic acids in that the usual nitrogen atom is replaced by a carbon atom.
• the invention provides sulfonyl hydroxamic acid derivatives.
• the compounds of the present invention inhibit various enzymes from the matrix metalloproteinase family, predominantly stromelysin and gelatinase, and hence are useful for the treatment of matrix metallo endoproteinase diseases such as osteoporosis, tumor metastasis (invasion and growth), periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, inflammation, asthma, and other diseases related to connective tissue degradation.
• matrix metallo endoproteinase diseases such as osteoporosis, tumor metastasis (invasion and growth), periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, inflammation, asthma, and other diseases related to connective tissue degradation.
• EP 0780 386 A1 discloses matrix metalloproteinases inhibitors useful in the treatment of mammals having disease states alleviated by the inhibition of such matrix metalloproteinases.
• the compounds of the present invention are novel and distinct from the above hydroxamic acids in that they have a hydroxy, amino group or fluoro on the ⁇ -position and two hydrogen atoms at the ⁇ -position of the hydroxamate group.
• R 1 is
• R 2 is
• R 3 is
• R 4 is
• R 7 is
• R 9 and R 10 are the same and different and are
• aryl is monocarbocyclic, or bicarbocyclic aromatic moiety
• het is 5- to 10-membered unsaturated monomonocyclic or bicyclic heterocyclic moiety having one to three atoms selected from the group consisting of oxygen, nitrogen, and sulfur;
• Q is 5- to 10-membered saturated monocyclic or bicyclic heterocyclic moiety having one to two atoms selected from the group consisting of oxygen, nitrogen, and sulfur; aryl, het, C 1-12 alkyl, C 1-4 alkyl C 2-12 alkenyl, C 2-12 alkynyl, —C 3-8 cycloalkyl, —C 3-8 cycloalkenyl, Q and phenyl being optionally substituted;
• the compounds of the present invention inhibit various enzymes from the matrix metalloproteinase family, predominantly stromelysin and gelatinase, and hence are useful for the treatment of matrix metallo endoproteinase diseases.
• the carbon content of various hydrocarbon containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety; i.e., the prefix C i-j defines the number of carbon atoms present from the integer “i” to the integer “j”, inclusive.
• C 1-4 alkyl refers to alkyl of one to four carbon atoms, inclusive, or methyl, ethyl, propyl, butyl and isomeric forms thereof.
• aryl, het, C 1-4 alkyl, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, Q and phenyl may be substituted as appropriate.
• Aryl is preferably substituted with C 1-4 alkyl, C 1-4 alkoxy, phenyl, O-phenyl, het, O-het, halo such as fluoro, chloro, bromo, OH, —NO 2 , —CN, —CF 3 , —N(R 3 ) 2 such as —N(C 1-4 alkyl) 2 , —SR 3 , —SO 2 (C 1-4 alkoxy), —(CH 2 ) h -het; —C( ⁇ O)R 3 or —NHC( ⁇ O)R 3 ; het is preferably substituted with C 1-4 alkyl, pheny, phenoxy or halo; C 1-12 alkyl is preferably substituted with one to three halo, CN, —NO 2 or —CF 3 ; —N(R 3 ) 2 such as —N(C 1-4 alkyl) 2 , —SR 3 or —OH; C 2-12
• the optional substituents of —(CH 2 ) h -aryl are selected from C 1-4 alkyl, C 1-4 alkoxy, phenyl, O-phenyl, het, O-het, halo, —NO 2 , —CF 3 , —CN, or —N(C 1-4 alkyl) 2 ;
• the optional substituents of —(CH 2 ) h -het are selected from C 1-4 alkyl, phenyl, phenoxy, het, or halo;
• the optional substituents of C 1-12 alkyl are one to three halo, —CN, —NO 2 , —CF 3 , —N(R 3 ) 2 , —SR 3 , or OH;
• the optional substituents of C 2-12 alkenyl and C 2-12 alkynyl are one to three halo, —CN,
• the optional substituents of —(CH 2 ) h -aryl are one to three C 1-4 alkyl, C 1-4 alkoxy, —CF 3 —OH, —NO 2 , —CN, —N(R 3 ) 2 , —SR 3 , —SO 2 (C 1-4 alkoxy), —C( ⁇ O)R 3 , —NHC( ⁇ O)R 3 , one to five halo;
• the optional substituents of —(CH 2 ) h -het are one to two C 1-4 alkyl, or halo;
• the optional substituents of —(CH 2 ) h -Q are one to three C 1-4 alkyl, C 1-4 alkoxy, halo, oxo or phenyl; in the meanings of R 3 the optional substituents of —(CH 2 ) h -phenyl are one to three C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkoxy
• C 1-4 alkyl refers to an alkyl group having one to four, four to eight, one to twelve, or one to eighteen carbon atoms respectively such as: for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl and their isomeric forms thereof, preferably an alkyl group of R 1 having four to eight carbon atoms, and an alkyl group of R 2 having one to eight carbon atoms.
• C 2-12 alkenyl and “C 4-8 alkenyl” refer to at least one double bond alkenyl group having two to twelve carbon atoms respectively such as; for example, ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, heptdienyl, octenyl, octadienyl, octatrienyl, nonenyl, undecenyl, dodecenyl, and their isomeric forms thereof, preferably an alkenyl group of R 1 having four to eight carbon atoms, and an alkenyl group of R 2 having two to eight carbon atoms.
• C 2-12 alkynyl refers to at least one triple bond alkynyl group having two to twelve carbon atoms such as; for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, octadiynyl, octatriynyl, nonynyl, nonediynyl, and their isomeric forms thereof, preferably an alkynyl group of R 1 having four to eight carbon atoms, and an alkenyl group of R 2 having two to eight carbon atoms.
• C 3-8 cycloalkyl refers to a cycloalkyl having three to eight carbon atoms such as; for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and their isomeric forms thereof, preferably a cycloalkyl group having five or six carbon atoms.
• C 3-8 cycloalkenyl refers to a cycloalkenyl having three to six or three to eight carbon atoms such as; for example, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyctooctenyl, and their isomeric forms thereof, preferably a cycloalkyl group having five or six carbon atoms.
• C 1-4 alkoxy refers to an alkyl group having one to four, one to six, or one to eight carbon atoms respectively attached to an oxygen atom of hydroxyl group such as; for example, methoxy, ethoxy, propyloxy, butyloxy, pentyloxy, hexyloxy, heptyloxy, or octyloxy and their isomeric forms thereof.
• aryl refers to monocarbocyclic or bicarbocyclic aromatic moiety such as; for example phenyl, naphthyl, and biphenyl. Each of these moieties may be substituted as appropriate.
• Aryl is preferably phenyl or phenyl substituted with C 1-4 alkyl, C 1-4 alkoxy, fluoro, chloro, bromo, —NO 2 , —CF 3 , —N(C 1-4 alkyl) 2 , —C( ⁇ O)R 3 , or —NHC( ⁇ O)R 3 .
• heterocyclic refers to a 5- to 10-membered unsaturated moncyclic or bicyclic heterocyclic moiety having one or more atoms selected from the group consisting of oxygen, nitrogen, and sulfur such as; for example, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, 3-pyrazinyl, 2-quinolyl, 3-quinolyl, 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 2-quinazolinyl, 4-quinazolinyl, 2-quinoxalinyl, 1-phthalazinyl, 2-imidazolyl, 4-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl,
• Q refers to a 5- to 1 0-membered saturated monocyclic or bicyclic heterocyclic moiety having one to two atoms selected from the group consisting of oxygen, nitrogen, and sulfur such as, for example, piperidinyl, 2-, 3-, or 4-piperidinyl, [1,4]piperazinyl, 2- or 3-morpholinyl, thiomorpholinyl, dioxolanyl, imidazolidinyl, [1,3]oxathiolanyl, [1,3]oxazolidinyl, pyrrolidinyl, butyrolactamyl, butyrolactamyl, succinimidyl, glutarimidyl, valerolactamyl, 2,5-dioxo-[1,4]-piperazinyl, pyrazolidinyl, 3-oxopyrazolidinyl, 2-oxo-imidazolidinyl, 2,4-dioxo-imidazolid
• halo refers to fluoro, chloro, bromo, or iodo, preferably fluoro, chloro, or bromo.
• salts refers to acid addition salts useful for administering the compounds of this invention and include hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate, propionate, lactate, mesylate, maleate, malate, succinate, tartrate, citric acid, 2-hydroxyethyl sulfonate, fumarate and the like. These salts may be in hydrated form. Some of the compounds of this invention may form metal salts such as sodium, potassium, calcium and magnesium salts and these are embraced by the term “pharmaceutically acceptable salts”.
• the compounds of formula I of this invention contain a chiral center at the ⁇ -position of hydroxamic acids, as such there exist two enantiomers or a racemic mixture of both.
• This invention relates to both the enantiomers, as well as mixtures containing both the isomers.
• additional chiral centers and other isomeric forms may be present in any of the R 2 groups, and this invention embraces all possible stereoisomers and geometric forms in this group.
• R 1 is preferably n-butyl, isobutyl, 1-methylpropyl, tert-butyl, n-pentyl, 3-methybutyl, n-hexyl, n-heptyl, n-octyl, phenyl, 4-methylphenyl, 4-ethylphenyl, 4-tert-butylphenyl, 4-isopropylphenyl, 4-chlorophenyl, 4-bromophenyl, 4-fluorophenyl, 4-trifluoromethylphenyl, 4-methoxyphenyl, 4-ethoxyphenyl, 4-n-butoxyphenyl, benzyl, 4-phenylbenzyl, 2-, 3-, or 4-fluorobenzyl, 2-, 3-, 4-chlorobenzyl, 2-, 3-, 4-bromobenzyl, 4-ethoxybenzyl, 4-phenylphenyl (i.e., biphenyl), 4-chlorobenz
• R 1 is n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, phenyl, 4-methylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 4-chlorophenyl, 4-bromophenyl, 4-fluorophenyl, 4-methoxyphenyl, 4-butoxyphenyl, benzyl, 4-fluorobenzyl, 4-chlorobenzyl, 4-bromobenzyl, 4-ethoxybenzyl, 4-phenylphenyl,4-n-butylphenyl, biphenyl, 4-chlorobiphenyl, 4-phenoxyphenyl, 4-(pyrid-4-yl)phenyl, and 4-(pyrid-4-yl)oxyphenyl.
• R 2 is preferably 1-cyano-1-phenyl methyl, 2-cyano ethyl, 2-phenylethyl, 2-bromo-2-phenylethyl, 2-bromoethyl, propyl, isopropyl, 3-chloropropyl, 3-bromopropyl, n-butyl, isobutyl, 3-methylbutyl, 1-methylpropyl, tert-butyl, n-pentyl, 3-methybutyl, n-hexyl, n-heptyl, n-octyl, n-hexadecyl, n-octadecyl, 2-propenyl, 2-propynyl, 3-butenyl, 4-pentenyl, 3-butenynyl, 4-pentenynyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, 2-cyclohexyleth
• R 2 is (4-methoxy-benzenesulfonyl)methyl, (4-fluorobenzenesulfonyl)methyl, (4-phenylbenzenesulfonyl)methyl, (4-n-butylphenylsulfonyl)methyl, benzenecarbonylamino, cyclopentanecarbonylamino, piperazinyl-methyl, 4-(methanesulfonyl)piperazinylmethyl, morpholinomethyl, (1-methylhydantoin-3-yl)methyl, (1,5,5-trimethylhydantoin-3-yl)methyl, (1-butylhylhydantoin-3-yl)methyl, 2-(1-methylhydantoin-3-yl)methyl-2-methylethyl, phenylthiomethyl, (2-methoxy)phenylthiomethyl, benzylthiomethyl, (pyrid-2-yl)thiomethyl, (pyrid-2
• Y is preferably a hydroxy group.
• the compounds of this invention can be prepared in accordance to the process discussed below.
• R 1 and R 2 are the groups as defined previously.
• Substituted malonate esters 2 are either obtained commercially, or can be readily prepared from structure 1 by methods well known to those skilled in the art. For example, reaction of an enolate of structure 1, generated by an appropriate base in an appropriate solvent, with an alkylating agent R 2 -I (I is bromo, chloro, tosylate, mesylate, epoxides, etc.) provides the desired substituted malonate esters 2. See: Organic Synthesis, Vol. 1, p 250 (1954); Organic Synthesis, Vol. 3, p 495 (1955).
• Compound 2 is hydrolyzed to mono-acid compound 3 by reaction with one equivalent of an appropriate base such as alkali hydroxide in an appropriate solvent at a temperature ranging from 0° C. to 30° C.
• an appropriate base such as alkali hydroxide
• compound 3 is converted to acrylic esters 4.
• acrylic esters 4 are commercially available.
• Acrylic esters 4 may be converted to glycidic esters 5 by oxidation with meta-chloroperoxybenzoic acid (MCPBA) in refluxing ethylene dichloride in the presence of a radical inhibitor such as 4,4′-thiobis-(6-t-butyl-3-methyl-phenol). See: J.
• MCPBA meta-chloroperoxybenzoic acid
• a thiol (H—SR 1 ) is added to the glycidic ester 5 at room temperature to afford sulfide esters 6 in the presence of a base such as sodium hydride in dry THF, or potassium carbonate in toluene, or a tertiary amine in chloroform.
• a base such as sodium hydride in dry THF, or potassium carbonate in toluene, or a tertiary amine in chloroform.
• the resultant sulfides 6 are readily oxidized to sulfones 7 by an oxidizing agent such as MCPBA in an appropriate solvent such as methylene chloride, or using hydrogen peroxide in acetic acid as solvent.
• esters 5 may be converted to sulfones 7 directly by reaction with sodium sulfinate salts in solvents such as DMF or toluene.
• the esters can be hydrolyzed by procedures well known in the art such as using 6N HCl and refluxing for 10 to 20 hours or using iodotrimethylsilane in chloroform, or by saponification with aqueous alkali in alcoholic solvents at 0° C. to room temperature, to afford free acids 8.
• Coupling of acids 8 with hydroxylamine hydrochloride to form hydroxamates 10 may be achieved by several routes well known to those skilled in the art.
• acids 8 can be activated by chloroethylformate in dry THF or a similar compatible solvent, or by a carbodiimide condensing agent such as EDC, with or without HOBT, in DMF and methylene chloride. A tertiary amine is required in both situations. The subsequent reaction of activated 8 with hydroxylamine provides the desired hydroxamic acid derivatives.
• acids 8 may be condensed, using the same reagents as described above, or using two equivalents of EDC in aqueous THF, with benzyl-protected hydroxylamine hydrochloride, to produce the protected hydroxamates 9.
• Compounds 9 are often easier to purify, and may readily be hydrogenolytically cleaved to the free hydroxamates 10 by a palladium catalyst in alcoholic solvents.
• Other protected hydroxylamines such as tert-butyl hydroxylamine may also be used, and the free hydroxamic acid can be obtained by treating it with trifluoroacetic acid.
• a second method of preparing the compounds of the invention particularly applicable to compounds of formula I wherein the R 2 group contains heteroatoms is to utilize commercially available bromomethyl acrylic acid esters such as 11, as shown in Scheme II. Treatment of 11 with thiols affords compounds 12. The reaction may be accomplished in dioxane, ethanol, toluene, or other appropriate solvent, at room temperature or reflux, with a base such as sodium bicarbonate or piperidine. See: Annelen, Vol. 564, pp 73-78 (1949).
• Ester 11 may also be converted directly to the sulfone 13 by treatment with sodium sulfinate salts in DMF, toluene, methanol, or other appropriate solvent at room temperature or reflux, with or without sodium iodide as catalyst. See: Tetrahedron Lett., Vol. 28, pp 813-816 (1987).
• Sulfides 12 or sulfones 13 can be oxidized to glycidic esters 14 by oxidation with a sufficient amount of MCPBA in refluxing ethylene dichloride in the presence of a radical inhibitor such as 4,4′-thiobis-(6-t-butyl-3-methyl-phenol), as referenced above.
• the glycidic esters 14 may be reacted with nucleophilic compounds W—H or alkaline salts thereof (wherein W is a group attached via a heteroatom such as oxygen, nitrogen, sulfur, or halogen) to afford the—hydroxy esters 7 (R 2 ⁇ CH 2 —W).
• W is a group attached via a heteroatom such as oxygen, nitrogen, sulfur, or halogen
• These reactions may be accomplished in methanol, DMF, toluene, or other appropriate solvents at room temperature or reflux. See: Tetrahedron, Vol. 51, pp 11841-11854 (1995) for an example of this reaction.
• Nucleophilic addition to glycidic esters may be facilitated by coordinating ions such as Mg 2+ or other species such as titanium alkoxides. See: Tetrahedron Lett., Vol.
• Scheme III illustrates the special case of Scheme II wherein glycidic ester 14 is reacted with a thiol or thiolate, as the nucleophile W—H or its alkaline salt, to afford the ⁇ -hydroxy esters 7 (R 2 ⁇ —CH 2 —S—R4).
• the reaction may be accomplished in THF, toluene, or other appropriate solvent, with the thiol and an appropriate base such as sodium hydride or potassium carbonate, at room temperature or reflux.
• These esters may be oxidized to the bis-sulfone esters 15 with MCPBA in methylene chloride, or hydrogen peroxide in acetic acid.
• the bis-sulfone esters 15 may be prepared directly from glycidic esters 14 by reaction with the sodium sulfinate salts in DMF, toluene, methanol, or other appropriate solvent at room temperature or reflux, with or without sodium iodide as catalyst.
• Hydrolysis of bis-sulfone esters 15 to the carboxylic acids 8 (R 2 ⁇ —CH 2 —S(O) 2 —R 4 ), and subsequent conversion to hydroxamic acids 10 (R 2 ⁇ —CH 2 —S(O) 2 —R 4 ) may be accomplished in accordance with the methods described in Scheme 1. In the special case wherein R 1 is the same as R 4 , the resulting hydroxamic acids are achiral molecules.
• Scheme V illustrates a method whereby compounds of this invention having a heterocyclic moiety may be prepared.
• Glycidic esters 14 may be reacted with t-butoxycarbonyl (Boc)-protected aminoacrylonitrile, for example, according to the methods of Scheme IV, to afford initially the oxazoline esters 17, and then the ⁇ -hydroxy esters 18 (R 2 ⁇ —CH 2 —NHCOCH 2 NHBoc).
• Scheme VI describes a method of preparing compounds of formula I, wherein Y ⁇ —NH 2 or —NHR 9 , via the glycidic esters 5.
• reaction of glycidic esters 5 with sodium azide in aqueous ethanol affords the azido alcohols 21.
• Refluxing the azido alcohols with triphenylphosphine in acetonitrile generates the aziridines 22.
• the aziridines undergo ring opening with thiol HSR 1 (followed by oxidation to the sulfone with MCPBA) or with sulfinate salts directly to afford the ⁇ -amino esters 23.
• the present invention also provides novel compounds of formula 8
• compositions of this invention may be prepared by combining the compounds of formula I of this invention with a solid or liquid pharmaceutically acceptable carrier, and optionally, with pharmaceutically acceptable adjuvants and excipients employing standard and conventional techniques.
• Solid form compositions include powders, tablets, dispersible granules, capsules and suppositories.
• a solid carrier can be at least one substance which may also function as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, tablet disintegrating agent, and encapsulating agent.
• Inert solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, cellulosic materials, low melting wax, cocoa butter, and the like.
• Liquid form compositions include solutions, suspensions and emulsions.
• solutions of the compounds of this invention dissolved in water, water-propylene glycol, and water-polyethylene glycol systems, optionally containing conventional coloring agents, flavoring agents, stabilizers and thickening agents.
• composition is provided by employing conventional techniques.
• composition is in unit dosage form containing an effective amount of the active component, that is, the compounds of formula I according to this invention.
• the quantity of active component that is the compounds of formula I according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application method, the potency of the particular compound and the desired concentration. Generally, the quantity of active component will range between 0.5% to 90% by weight of the composition.
• the compounds or pharmaceutical compositions thereof will be administered orally, parenterally and/or topically at a dosage to obtain and maintain a concentration, that is, an amount, or blood-level of active component in the patient undergoing treatment which will be effective to inhibit such enzymes.
• a dosage that is, an amount, or blood-level of active component in the patient undergoing treatment which will be effective to inhibit such enzymes.
• an effective amount of the active compound will be in the range of about 0.1 to about 100 mg/kg. It is to be understood that the dosages may vary depending upon the requirements of the patient, the severity of connective tissue degradation being treated, and the particular compounds being used.
• the initial dosage administered may be increased beyond the above upper level in order to rapidly achieve the desired blood-level or the initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation. If desired, the daily dose may also be divided into multiple doses for administration, e.g., two to four times per day.
• the compounds of the present invention inhibit various enzymes from the matrix metalloproteinase family, predominantly stromelysin and gelatinase, and hence are useful for the treatment of matrix metallo endoproteinase diseases such as osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenias such as osteoporosis, tumor metastasis (invasion and growth), periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, inflammation, asthma and other diseases related to connective tissue degradation.
• matrix metallo endoproteinase diseases such as osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenias such as osteoporosis, tumor metastasis (invasion and growth), periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, inflammation, asthma and other diseases related to connective tissue degradation.
• matrix metallo endoproteinase diseases such as osteoarthriti
• compositions for parenteral administration will generally contain a pharmaceutically acceptable amount of the compounds according to formula I as a soluble salt (acid addition salt or base salt) dissolved in a pharmaceutically acceptable liquid carrier such as; for example, water-for-injection and a suitably buffered isotonic solution having a pH of about 3.5-6.
• a pharmaceutically acceptable liquid carrier such as; for example, water-for-injection and a suitably buffered isotonic solution having a pH of about 3.5-6.
• Suitable buffering agents include; for example, trisodium orthophosphate, sodium bicarbonate, sodium citrate, N-methylglucamine, L(+)-lysine and L(+)-arginine, to name a few.
• the compounds according to formula I generally will be dissolved in the carrier in an amount sufficient to provide a pharmaceutically acceptable injectable concentration in the range of about 1 mg/ml to about 400 mg/ml.
• the resulting liquid pharmaceutical composition will be administered so as to obtain the above-ment
• Step 1 Preparation of 2-[(4-methoxybenzenethio)methyl]-acrylic acid, ethyl ester.
• Step 2 Preparation of 2-(4-methoxybenzenesulfonyl)methyl-oxiranecarboxylic acid, ethyl ester.
• Step 3 Preparation of 2-hydroxy-2-[(4-methoxybenzenesulfonyl)methyl]-3-(4-phenylbenzenethio)-propionic acid, ethyl ester.
• Step 4 Preparation of 2-hydroxy-2-[(4-methoxybenzenesulfonyl)methyl]-3-(4-phenylbenzenesulfonyl)-propionic acid, ethyl ester.
• Step 5 Preparation of 2-hydroxy-2-[(4-methoxybenzenesulfonyl)methyl]-3-(4-phenylbenzenesulfonyl)-propionic acid.
• Step 6 Preparation of N-benzyloxy-2-hydroxy-2-[(4-methoxybenzenesulfonyl)methyl]-3-(4-phenylbenzenesulfonyl)-propionamide.
• Step 7 Preparation of N-hydroxy-2-hydroxy-2-[(4-methoxybenzenesulfonyl)methyl]-3-(4-phenylbenzenesulfonyl)-propionamide.
• Step 8 Racemic N-hydroxy-2-hydroxy-2-[(4-methoxybenzenesulfonyl)methyl]-3-(4-phenylbenzenesulfonyl)-propionamide is resolved by chiral chromatography to yield enantiomer A and enantiomer B.
• Step 1 Preparation of 2-hydroxy-2-[(4-methoxybenzenesulfonyl)methyl]-3-(N-benzenecarbonylamino)-propionic acid, ethyl ester.
• Step 2 Preparation of 2-hydroxy-2-[(4-methoxybenzenesulfonyl)methyl]-3-(N-benzenecarbonylamino)-propionic acid.
• Step 3 Preparation of N-hydroxy-2-hydroxy-2-[(4-methoxybenzenesulfonyl)methyl]-3-(N-benzenecarbonylamino)-propionamide.
• Step 1 Preparation of 2-hydroxy-2-[(4-methoxybenzenesulfonyl)methyl]-3-(N-(4-methoxybenzenecarbonyl)amino)-propionic acid.
• Step 2 Preparation of N-hydroxy-2-hydroxy-2-[(4-methoxybenzenesulfonyl)methyl]-3-(N-(4-methoxybenzenecarbonyl)amino)-propionamide.
• the solvent is removed under reduced pressure, and the residue is dissolved in ethyl acetate.
• the organic layer is washed with 1N sodium hydrogen sulfate, 5% sodium bicarbonate, and saturated brine and dried over magnesium sulfate.
• the solvent is removed to yield 71 mg of white solid which is recrystallized from methanol.
• the tert-butyl protecting group is removed by treatment with 50% trifluoroacetic acid in methylene chloride for 24 hours.
• the solvents are removed, and the crude product is purified by reverse phase chromatography on a C18 Vydac column using a water/acetonitrile elution system to yield the title compound as a white solid.
• Inhibitory activity is evaluated in one or more of the MMP enzymes (stromelysin, gelatinase, and collagenase) in vitro using particle concentration fluorescence assay.
• An inhibitor binds to MMP enzymes which prevents the degradation of a substrate by stromelysin, gelatinase, or collagenase.
• the substrate has attached to it a fluorescein and a biotin moiety.
• the intact substrate then binds to an avidin-coated particle via the biotin moiety. Once the particle is washed and dried, a fluorescent signal is generated since the fluorescent group is attached to the particle.
• testing compounds are dissolved in DMSO to the desired concentration, then the solutions are diluted to 1:5 with MMP buffer (50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 0.02% NaN 3 ). Serial two-fold dilutions of each compound are prepared. A concentrated, activated enzyme solution is transferred into each plate of the testing compounds, and the mixture is incubated at room temperature for 15 minutes. Thawed MMP substrate is then added into all plates, and the plates are incubated in the dark for 1-3 hours at room temperature.
• MMP buffer 50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 0.02% NaN 3

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pulmonology (AREA)
• Urology & Nephrology (AREA)
• Physical Education & Sports Medicine (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Biomedical Technology (AREA)
• Oncology (AREA)
• Dermatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Pyridine Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Plural Heterocyclic Compounds (AREA)
• Thiazole And Isothizaole Compounds (AREA)
• Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Publications (1)

Family

ID=22108985

Family Applications (2)

Family Applications After (1)

Country Status (24)

Cited By (3)

Families Citing this family (20)

Citations (1)

Family Cites Families (9)

• 1998
  • 1998-11-18 US US09/530,965 patent/US20030166687A1/en not_active Abandoned
  • 1998-11-18 PT PT98966869T patent/PT1037868E/pt unknown
  • 1998-11-18 HU HU0100812A patent/HUP0100812A3/hu unknown
  • 1998-11-18 JP JP2000522069A patent/JP2001524462A/ja active Pending
  • 1998-11-18 AU AU25405/99A patent/AU763113B2/en not_active Ceased
  • 1998-11-18 PL PL98341153A patent/PL341153A1/xx unknown
  • 1998-11-18 CA CA002310401A patent/CA2310401A1/fr not_active Abandoned
  • 1998-11-18 ES ES98966869T patent/ES2192349T3/es not_active Expired - Lifetime
  • 1998-11-18 EA EA200000551A patent/EA003585B1/ru not_active IP Right Cessation
  • 1998-11-18 DK DK98966869T patent/DK1037868T3/da active
  • 1998-11-18 EP EP98966869A patent/EP1037868B1/fr not_active Expired - Lifetime
  • 1998-11-18 UA UA2000052847A patent/UA66818C2/uk unknown
  • 1998-11-18 BR BR9814699-8A patent/BR9814699A/pt not_active Application Discontinuation
  • 1998-11-18 NZ NZ503997A patent/NZ503997A/en unknown
  • 1998-11-18 TR TR2000/01391T patent/TR200001391T2/xx unknown
  • 1998-11-18 AT AT98966869T patent/ATE232192T1/de not_active IP Right Cessation
  • 1998-11-18 KR KR1020007005530A patent/KR20010032319A/ko not_active Application Discontinuation
  • 1998-11-18 WO PCT/IB1998/002154 patent/WO1999026909A2/fr not_active Application Discontinuation
  • 1998-11-18 DE DE69811273T patent/DE69811273T2/de not_active Expired - Fee Related
  • 1998-11-18 IL IL13558698A patent/IL135586A0/xx unknown
  • 1998-11-18 CN CNB988106914A patent/CN1168709C/zh not_active Expired - Fee Related
  • 1998-11-20 US US09/196,190 patent/US6437177B1/en not_active Expired - Fee Related
• 2000
  • 2000-04-17 BG BG104346A patent/BG104346A/xx unknown
  • 2000-04-28 IS IS5475A patent/IS1954B/is unknown
  • 2000-05-15 NO NO20002505A patent/NO20002505L/no unknown

Patent Citations (1)

Also Published As

Similar Documents

Legal Events